Nasal Drug Delivery: Opportunities, Challenges, and Formulation Strategies
Technical Article
Published: September 2025
Authors: Dr. Jon Lenn, Dr. Charles Evans, Dr. Jon Volmer
Advancing Alternative Drug Delivery Through Scientific Expertise
Nasal drug delivery is an increasingly important route of administration for local, systemic, and central nervous system therapies. Compared with oral and injectable dosage forms, nasal formulations can enable rapid onset of action, reduce systemic exposure, and improve patient adherence. However, biological barriers, rapid clearance mechanisms, and device-dependent delivery introduce formulation challenges that require specialized expertise.
In this technical article, MedPharm examines key considerations for nasal drug delivery within the broader context of alternative topical and transepithelial routes of administration. The article highlights route-specific challenges, formulation and device strategies, and the role of preclinical models in de-risking development and accelerating timelines.
What’s Covered in This Technical Article
- Core principles of nasal drug delivery and biological barriers
- Common formulation challenges and development considerations
- Strategies to optimize residence time, absorption, and targeting
- The impact of formulation–device interactions on delivery performance
- How preclinical nasal models support formulation selection and reduce risk
📥 Download the Technical Article
Complete the form to access the full technical article and explore MedPharm’s approach to nasal drug delivery and alternative routes of administration.
This is placeholder text. Lorem Ipsum is simply dummy text of the printing and typesetting industry. This is placeholder text. Lorem Ipsum is simply dummy text of the printing and typesetting industry.
This is placeholder text. Lorem Ipsum is simply dummy text of the printing and typesetting industry. This is placeholder text. Lorem Ipsum is simply dummy text of the printing and typesetting industry. This is placeholder text. Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Download The Article >
This one-page overview highlights MedPharm’s end-to-end capabilities in topical, transdermal, and transepithelial drug development. From early-stage formulation and in vitro testing through clinical trial material supply and commercial manufacturing, MedPharm supports programs at every stage to accelerate development and reduce risk.
Download Overview
This case study shows how MedPharm, in collaboration with GSK and the University of Reading, demonstrated the skin penetration and biological activity of a large aptamer using advanced skin models. The findings challenge traditional molecular weight limits in topical drug delivery and highlight the potential for large-molecule therapies in dermatology.
This case study shows how MedPharm worked with Reckitt scientists to develop clinically relevant pharynx models for comparing drug delivery from a throat spray and a lozenge formulation. Using ex vivo and human tissue models, the team demonstrated equivalent flurbiprofen permeation across both dosage forms and supported the determination of a clinically relevant dose. These results enabled confident evaluation of formulation performance and helped inform product strategy.
This case study shows how MedPharm used process development to support clinical trial supply for a complex topical formulation. By identifying critical process parameters and optimizing manufacturing conditions, the team improved product consistency and reduced scale-up risk. The optimized process enabled reliable, reproducible production of clinical batches and ensured on-time delivery for a Phase 2 clinical trial.
The aim of process development is to establish optimal process parameters and conditions for future large-scale batches or commercialization, ensuring that the product can be successfully manufactured in compliance with required quality and regulatory standards. This ultimately means that an in-depth understanding of the formulation is key.
In a recent two-part article with Manufacturing Chemist, Joseph Holt, Head of Process Development at MedPharm, explores the challenges facing developers when scaling-up processes for semisolid drug product production and highlights the additional difficulties associated with generic drug development and manufacturing.
